Esperion names chief medical officer

ANN ARBOR—Officials at the Ann Arbor cholesterol drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as chief medical officer, effective immediately. …

Esperion names new president, CEO

ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to …

Esperion secures $50M in financing

ANN ARBOR—Esperion Therapeutics (NASDAQ: ESPR), developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide …

Esperion targets another cholesterol-buster

ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …